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AbstrACt
Objectives The National Chlamydia Screening 
Programme (NCSP) in England opportunistically screens 
eligible individuals for chlamydia infection. Retesting is 
recommended three3 months after treatment following a 
positive test result, but no guidance is given on how local 
areas should recall individuals for retesting. Here , we 
compare cost estimates for different recall methods to 
inform the optimal delivery of retesting programmes.
Design Economic evaluation.
setting England.
Methods We estimated the cost of chlamydia retesting 
for each of the six most commonly used recall methods 
in 2014 based on existing cost estimates of a chlamydia 
screen. Proportions accepting retesting, opting for 
retesting by post, returning postal testing kits and retesting 
positive were informed by 2014 NCSP audit data. Health 
professionals ‘sense-checked’ the costs.
Primary and secondary outcomes Cost and adjusted 
cost per chlamydia retest; cost and adjusted cost per 
chlamydia retest positive.
results We estimated the cost of the chlamydia retest 
pathway, including treatment/follow-up call, to be between 
£45 and £70 per completed test. At the lower end, this 
compared favourably to the cost of a clinic-based screen. 
Cost per retest positive was £389–£607. After adjusting for 
incomplete uptake, and non-return of postal kits, the cost rose 
to £109–£289 per completed test (cost per retest positive: 
£946–£2,506). The most economical method in terms of 
adjusted cost per retest was no active recall as gains in 
retest rates with active recall did not outweigh the higher 
cost. Nurse-led client contact by phone was particularly 
uneconomical, as was sending out postal testing kits 
automatically.
Conclusions Retesting without active recall is more 
economical than more intensive methods such as recalling by 
phone and automatically sending out postal kits. If sending a 
short message service (SMS) could be automated, this could 
be the most economical way of delivering retesting. However, 
patient choice and local accessibility of services should be 
taken into consideration in planning.
IntrODuCtIOn 
Chlamydia trachomatis (chlamydia) is the 
most commonly diagnosed bacterial sexually 
transmitted infection (STI) in England.1 
Since 2003, there has been a National Chla-
mydia Screening Programme (NCSP) in 
England which opportunistically tests sexu-
ally active people aged 15–24 years.2 NCSP 
guidelines recommend retesting 3 months 
after treatment for chlamydia.3 British Asso-
ciation for Sexual Health and HIV (BASHH) 
national guidelines recommend retesting 
people under 25 years of age 3–6 months 
after treatment.4 No guidance is given by 
either the NCSP or BASHH on how local 
areas should recall individuals for retesting, 
which can be done in many ways. The 2014 
NCSP retesting audit5 found that the most 
common methods of recalling individuals for 
strengths and limitations of this study
 ► We compared the cost of the chlamydia retest 
pathway in England across the six most commonly 
used methods of recalling individuals for retesting, 
to enable local service planners to assess whether 
they are delivering retesting economically or should 
consider an alternative approach.
 ► Our cost estimates included both clinic retesting and 
retesting using postal kits.
 ► We incorporated incomplete uptake, and non-return 
of postal kits, to estimate cost based on actual pat-
terns of use.
 ► We did not specifically look at the effect of factors 
such as gender, country of birth, sexual orientation, 
perceived risk of infection and presence of symp-
toms on retest uptake and therefore cost, although 
no active recall is likely to be associated with similar 
or higher test positivity than active recall.
 ► We also did not consider other important factors 
besides cost such as the demography of the popu-
lation: for example, automatically sending out postal 
kits might be the only feasible option in rural areas, 
and indeed, on-line testing, which was not consid-
ered in our analysis, is likely to be the most econom-
ical method of all.
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retesting were as follows: (1) conversation with client at 
time of test result with no further reminder (32%); (2) 
reminder card given to client at time of test result with 
no further reminder (1%); (3) client sent a text message 
when retest due (29%); (4) client invited by phone call 
when retest due (8%); (5) testing kit posted to client’s 
chosen address when retest due (5%) and (6) retesting 
advised at follow-up call with client—text message sent at 
3 months (19%). The audit also measured overall retest 
rates for each recall method, which were calculated from 
the number that attended a clinic for a retest or returned 
a postal testing kit, divided by the total number recalled 
for retesting. This is different to retest uptake, which is the 
number that attended a clinic for a retest or ordered or 
were sent a postal testing kit, divided by the total number 
recalled for retesting, which has cost implications. Retest 
uptake was not measured by the audit. Unpublished data 
from the 2017 NCSP retesting audit (Erna Buitendam, 
personal communication) showed that, for the six most 
commonly used recall methods in the 2014 audit, retest 
rates significantly increased for method 1 (client-led) and 
method 5 (automatic postal test kit) between the 2014 
and 2017 audits.
Previous estimates exist for the cost of a clinic-based 
chlamydia screen.6 7 However, to our knowledge there are 
no estimates of the cost of a chlamydia retest, and how 
this varies by recall method. Specifically, we do not know 
the best way to balance getting the optimal number of 
people to retest versus the additional cost of delivering 
invitations or reminders to retest. Understanding how 
the cost of retesting varies depending on the approach 
taken is critical for an optimal programme delivery. Here, 
we present cost estimates for different recall methods 
in England, first for the retest pathway itself, and then 
for the adjusted cost per retest, allowing for incomplete 
uptake and non-return of postal kits, to impact on cost.
MethODs
We estimated the cost of chlamydia retesting in England 
using Microsoft Excel 2016 for each of the six most 
commonly used recall methods reported in the 2014 
NCSP retesting audit5 (table 1) as follows. First, we entered 
existing cost estimates for a chlamydia test from Pathway 
Analytics (costed for clinic-based chlamydia screening for 
2011), which excluding a follow-up call was around £456 
(online supplementary table 1).  We used this costing 
as given. We then added additional costs to reflect costs 
specifically associated with retesting, such as a nurse-led 
conversation about retesting after diagnosis, and issuing 
retest invitations/reminders (eg, by text message [SMS] 
or phone). A nurse-led conversation about retesting after 
diagnosis was assumed to involve only extra nurse time 
to additionally discuss retesting; other associated costs 
were assumed to be already factored into the cost of a 
first test. Both an SMS and a phone call were assumed to 
involve administration time and the cost of the SMS or 
call itself while the latter was assumed to also include both 
nurse time for the actual call and chasing time. In addi-
tion, we amended the clinic-based chlamydia test costs to 
allow for postal testing. Costs were then totalled across 
the following cost categories: cost of offering retesting, 
cost of delivering a retest, and cost of processing retest 
and giving results, as well as overall.
For each of the six recall methods, we costed both the 
retest pathway, and the adjusted cost per retest (online 
supplementary figure 1). The adjusted cost per retest 
accounts for incomplete uptake, and non-return of postal 
kits, within each cost category. For all methods except 
method 5 (automatic postal testing kit), we allowed 
clients to choose either to attend a clinic for retesting or 
to request a postal testing kit. Thus, for methods 1–4 and 
method 6, we incorporated the following parameters: 
retest uptake, the proportion who opt for postal testing, 
and the return rate of requested kits. Retest uptake for 
each of the six recall methods was fitted to overall retest 
rates from the 2014 NCSP audit,5 taking a value of 24% 
for the proportion of clients who opt for postal testing 
(also from the audit), and a value of 67% for the return 
rate of requested kits.8 For method 5, uptake was equiv-
alent to overall retest rate and was simply the return 
rate of postal kits (10%) from the 2014 NCSP audit.5 
Chlamydia retest positivity (12%), which informs the 
relative weight given to the cost of managing a positive 
retest result versus managing a negative retest result in 
the average cost of the chlamydia retesting pathway, was 
taken from the NCSP audit,5 and was averaged over all 
six recall methods due to small numbers by individual 
method. We also calculated the cost and adjusted cost 
per retest positive, ie, the cost of finding one positive 
retest incorporating the cost of other, negative retests, 
by dividing test costs by the chlamydia positivity. For a 
table of parameter values, see online supplementary 
table 2.
The time frame for calculating the parameter values 
was 10–14 weeks, corresponding to NCSP guidance for 
retesting. We sense-checked our retesting costs (online 
supplementary table 1) with health professionals. We 
conducted two sensitivity analyses. In the first sensitivity 
analysis, we replaced the parameters for the retesting 
pathway with those obtained from data for retesting done 
between 10 and 26 weeks (corresponding to BASHH 
guidance) (online supplementary table 2).  This simply 
allows more time for clients to retest: there is no addi-
tional contact with clients to remind them to retest. In 
the second sensitivity analysis, we altered staff salary costs 
from nurse bands to administrator bands for nurse-based 
costs associated with phone invitations to retest, managing 
a retest negative and a follow-up call at 3 months for those 
retesting positive (leaving the nurse-based costs associ-
ated with the initial retest conversation and managing 
a retest positive unchanged). The purpose of this was 
to show the difference in price that could be achieved if 
administrative staff instead of nurses contacted clients by 
phone, except where a lower band of advisor might not 
be appropriate.
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Since retest rates significantly increased for method 
1 (client-led) and method 5 (automatic postal test 
kit) between the 2014 and (unpublished) 2017 audits 
(P<0.05), we restricted our analyses to 2014 data only. 
However, we carried out an analysis of whether retest posi-
tivity was statistically significantly different for no active 
recall (method 1) versus active recall (methods 3 and 6) 
using both 2014 and 2017 audit data, since there was no 
statistically significant difference in the positivity rates for 
each of these methods when comparing 2014 and 2017 
data.
Patient and public involvement
Patients and the public were not involved in this analysis.
results
The estimated cost of the chlamydia retest pathway 
ranged from £45 to £70 per completed test, while the cost 
per retest positive ranged from £389 to £607 (table 1). 
Posting testing kits automatically with no further 
reminder (method 5) was the cheapest recall method, 
while methods involving inviting clients by phone to 
retest (methods 4 and 6) were the most expensive. After 
adjusting for incomplete uptake and non-return of postal 
kits, the cost per chlamydia retest ranged from £109 to 
£289 per completed test, while the cost per retest positive 
ranged from £946 to £2506. Here, the most economical 
recall method in terms of the adjusted cost per retest was 
no active recall (method 1). An SMS invitation (method 
3) increased retest rates for a comparatively small addi-
tional cost. The most expensive methods were still those 
involving inviting clients by phone to retest (methods 4 
and 6). This was despite these methods achieving higher 
retest rates (6% and 12% for methods 4 and 6, respec-
tively) compared with no active recall (5%). Sending 
postal testing kits out automatically (method 5) was also 
an uneconomical way of delivering a retest, due to the 
cost of non-returned kits. Retest positivity was not statis-
tically significantly different for no active recall (method 
1) versus active recall (methods 3 and 6) when 2014 and 
2017 audit data were combined.
Extending the retesting period to 10–26 weeks did 
not impact substantially on the chlamydia retesting 
pathway cost (range £45–£70) (table 1). However, the 
adjusted cost per retest incorporating incomplete uptake 
and non-return of kits was substantially lower (range 
£71–£126), as was the adjusted cost per retest positive 
(range £440–£883), than with a tighter retest window, 
particularly for automatically sending out postal kits 
(method 5). However, this assumed positivity was higher 
for the 10–26 week window across all methods. In any 
case, methods with no or else minimal active recall were 
still the most economical. Replacing nurse bands with 
administrator bands only had a substantial impact on 
costs for those methods where clients were contacted by 
phone to recall for retest (table 1).
DIsCussIOn
The estimated cost of the chlamydia retest pathway 
ranged from £45 to £70 per completed test, which at the 
cheapest end was very similar to the cost of a clinic-based 
chlamydia screen.6 7 The cost per retest positive, mean-
while, ranged from £389 to £607. Important differences 
were seen when uptake and kit return rates were varied. 
This is because successfully completed retests effectively 
absorbed the cost of incomplete retests. Here, the most 
economical recall method involved no active recall after 
the initial retest conversation. Sending out postal testing 
kits automatically was an expensive way of doing retesting 
because of wastage of kits. However, the most expensive 
methods involved contacting clients by phone to invite 
them to retest, primarily because of nurse time required.
When the retesting window was increased from 10–14 
weeks to 10–26 weeks, all methods of recall had a reduced 
adjusted cost per retest, due in part to a higher positivity 
for 10–26 weeks. However, a longer time window means 
there is further potential for onward transmission, so it 
is important clients are counselled on the best time to 
retest.
Active recall increased retest rates, but this did not 
outweigh the additional cost. We assumed that sending 
an SMS involved administration time to retrieve clients’ 
details from a database. In our analysis, we considered 
only the effect of altering staff salary costs from nurse 
bands to administrator bands for some nurse-based activ-
ities. If the time needed to send an SMS could be short-
ened by automating this process, then an SMS invitation 
or reminder could be an economical way of increasing 
retest rates. For example, if the cost of associated admin-
istration time is removed, then the adjusted cost per chla-
mydia retest is £88 and the adjusted cost per retest positive 
is £765, making sending an SMS the most economical way 
of delivering retesting. Conversations with health profes-
sionals during our study suggested that a shorter admin-
istration time to send an SMS was theoretically feasible. 
We did not find any evidence that retest positivity was 
different for active recall versus no active recall, meaning 
there is no evidence that active recall merely results in 
more negatives being tested. However, evidence from a 
retesting pilot in South-West England did show that those 
who retested without being actively recalled had higher 
chlamydia retest positivity than those who were actively 
recalled.8 Furthermore, the unpublished 2017 audit data 
showed a statistically significant increase in the retest rate 
for client-led retesting for 10–14 weeks compared with 
2014 (Erna Buitendam, personal communication), which 
could make no active recall even more economical than 
shown here.
Our analysis was done for the pathway cost of testing 
for chlamydia alone.6 Where chlamydia testing is done at 
the same time as testing for other STIs (such as gonor-
rhoea), the proportionate cost of testing for chlamydia 
will be reduced. Another consideration is that since our 
analysis was carried out, the estimated pathway cost has 
fallen, which will reduce costs further across all methods 
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of retesting. However, cost is not the only important factor 
to consider. For example, no active recall also had the 
lowest retest rate, although as noted above, active recall 
may not necessarily identify more infected people if those 
opting to retest self-select on the basis of their perceived 
risk or presence of symptoms. We also did not account 
for the effect on retest uptake of factors such as gender, 
location of services, country of birth and sexual orienta-
tion. The composition of the population is an important 
consideration in local planning: a large rural population, 
for example, might affect how retesting needs to be deliv-
ered. Given the much higher return rate for requested 
postal testing kits compared with kits sent out automat-
ically, online testing with automated recall is likely to be 
the most economical method of all, but was beyond the 
scope of this analysis.
Our analysis suggests that no active recall after the 
initial retest conversation is the most economical way of 
retesting, although an SMS invitation or reminder could 
be considered. Patient choice and accessibility of services 
should still be taken into consideration for local delivery 
planning and it is important that retest uptake is moni-
tored as this determines how economical retesting is.
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